Compare Stocks: DBVT, CLDX, IMNM, and BEAM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$29.66 +0.7%	$29.35	$18.72 ▼ $38.26	$3.06B	2.22	1.58 million shs	1.18 million shs
CLDX Celldex Therapeutics	$39.68 +0.8%	$39.07	$22.10 ▼ $45.14	$3.12B	0.84	739,878 shs	414,530 shs
DBVT DBV Technologies	$13.47 -1.7%	$14.58	$8.70 ▼ $26.18	$861.39M	-0.95	226,058 shs	43,079 shs
IMNM Immunome	$26.76 -1.5%	$24.96	$8.66 ▼ $30.06	$3.04B	2.13	1.12 million shs	562,127 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.68%	+1.16%	+9.57%	+0.88%	+58.10%
CLDX Celldex Therapeutics	+0.79%	+1.43%	-3.36%	+38.64%	+68.06%
DBVT DBV Technologies	-1.68%	-0.52%	-5.41%	-18.81%	+47.86%
IMNM Immunome	-1.47%	-2.94%	+4.86%	+44.03%	+161.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$29.66 +0.7%	$29.35	$18.72 ▼ $38.26	$3.06B	2.22	1.58 million shs	1.18 million shs
CLDX Celldex Therapeutics	$39.68 +0.8%	$39.07	$22.10 ▼ $45.14	$3.12B	0.84	739,878 shs	414,530 shs
DBVT DBV Technologies	$13.47 -1.7%	$14.58	$8.70 ▼ $26.18	$861.39M	-0.95	226,058 shs	43,079 shs
IMNM Immunome	$26.76 -1.5%	$24.96	$8.66 ▼ $30.06	$3.04B	2.13	1.12 million shs	562,127 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.68%	+1.16%	+9.57%	+0.88%	+58.10%
CLDX Celldex Therapeutics	+0.79%	+1.43%	-3.36%	+38.64%	+68.06%
DBVT DBV Technologies	-1.68%	-0.52%	-5.41%	-18.81%	+47.86%
IMNM Immunome	-1.47%	-2.94%	+4.86%	+44.03%	+161.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	65.21% Upside
CLDX Celldex Therapeutics	2.85	Moderate Buy	$56.08	41.34% Upside
DBVT DBV Technologies	2.71	Moderate Buy	$48.50	260.06% Upside
IMNM Immunome	2.85	Moderate Buy	$34.64	29.43% Upside

Current Analyst Ratings Breakdown

Latest DBVT, CLDX, IMNM, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
8/12/2026	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$31.00 ➝ $35.00
8/12/2026	IMNM Immunome	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/10/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00
8/7/2026	CLDX Celldex Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $53.00
7/29/2026	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $72.00
7/22/2026	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$54.00 ➝ $48.00
7/22/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$44.00 ➝ $40.00
7/22/2026	CLDX Celldex Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$67.00 ➝ $61.00
7/22/2026	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$62.00 ➝ $60.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$156.04M	19.63	N/A	N/A	$10.34 per share	2.87
CLDX Celldex Therapeutics	$158K	19,721.96	N/A	N/A	$9.10 per share	4.36
DBVT DBV Technologies	N/A	N/A	N/A	N/A	$2.55 per share	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	$4.62 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)

Latest DBVT, CLDX, IMNM, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	3.03%	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
CLDX Celldex Therapeutics	N/A	11.82	11.82
DBVT DBV Technologies	N/A	3.72	3.72
IMNM Immunome	N/A	15.08	15.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CLDX Celldex Therapeutics	N/A
DBVT DBV Technologies	71.74%
IMNM Immunome	44.58%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
CLDX Celldex Therapeutics	5.20%
DBVT DBV Technologies	1.06%
IMNM Immunome	7.21%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
CLDX Celldex Therapeutics	150	78.53 million	74.45 million	Optionable
DBVT DBV Technologies	80	62.88 million	62.21 million	Optionable
IMNM Immunome	40	113.58 million	105.39 million	Optionable

DBVT, CLDX, IMNM, and BEAM Headlines

Recent News About These Companies

Bank of New York Mellon Corp Acquires New Stake in Immunome, Inc. $IMNM

September 5 at 3:21 AM | marketbeat.com

Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 2 at 7:45 AM | businesswire.com

Wellington Management Group LLP Grows Position in Immunome, Inc. $IMNM

September 2 at 4:56 AM | marketbeat.com

The Manufacturers Life Insurance Company Buys Shares of 172,893 Immunome, Inc. $IMNM

September 2 at 4:48 AM | marketbeat.com

Deutsche Bank AG Invests $2.37 Million in Immunome, Inc. $IMNM

August 28, 2026 | marketbeat.com

BlackRock Inc. Takes $186.59 Million Position in Immunome, Inc. $IMNM

August 28, 2026 | marketbeat.com

Primecap Management Co. CA Acquires Shares of 4,581,431 Immunome, Inc. $IMNM

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Invests $12.59 Million in Immunome, Inc. $IMNM

August 25, 2026 | marketbeat.com

Bank of America Corp DE Boosts Stake in Immunome, Inc. $IMNM

August 21, 2026 | marketbeat.com

Immunome (NASDAQ:IMNM) Sets New 12-Month High - Should You Buy?

August 19, 2026 | marketbeat.com

Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Moderate Buy" from Analysts

August 18, 2026 | marketbeat.com

Dimensional Fund Advisors LP Decreases Stock Position in Immunome, Inc. $IMNM

August 16, 2026 | marketbeat.com

Immunome (NASDAQ:IMNM) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

HC Wainwright Issues Negative Forecast for Immunome Earnings

August 14, 2026 | marketbeat.com

Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon

August 13, 2026 | seekingalpha.com

Immunome (NASDAQ:IMNM) Director Sells 10,125 Shares

August 13, 2026 | insidertrades.com

Renaissance Technologies LLC Makes New Investment in Immunome, Inc. $IMNM

August 13, 2026 | marketbeat.com

Immunome (NASDAQ:IMNM) Reaches New 12-Month High Following Analyst Upgrade

August 13, 2026 | marketbeat.com

Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 10,125 Shares

August 12, 2026 | marketbeat.com

Insider Selling: Immunome (NASDAQ:IMNM) Director Sells 11,048 Shares

August 12, 2026 | marketbeat.com

Insider Selling: Immunome (NASDAQ:IMNM) Director Sells $1,633,892.93 in Stock

August 12, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, CLDX, IMNM, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$29.66 +0.20 (+0.68%)

As of 09/4/2026 04:00 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Celldex Therapeutics NASDAQ:CLDX

$39.68 +0.31 (+0.79%)

As of 09/4/2026 04:00 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

DBV Technologies NASDAQ:DBVT

$13.47 -0.23 (-1.68%)

As of 09/4/2026 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Immunome NASDAQ:IMNM

$26.76 -0.40 (-1.47%)

As of 09/4/2026 04:00 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DBVT, CLDX, IMNM, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DBVT, CLDX, IMNM, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DBVT, CLDX, IMNM, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, CLDX, IMNM, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

DBV Technologies NASDAQ:DBVT

Immunome NASDAQ:IMNM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DBVT, CLDX, IMNM, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DBVT, CLDX, IMNM, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DBVT, CLDX, IMNM, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, CLDX, IMNM, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

DBV Technologies NASDAQ:DBVT

Immunome NASDAQ:IMNM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools